The transplantation groups at OUS-Rikshospitalet
The focus of this research collaboration has been on pharmacokinetics topics, but also physiological investigations have been performed. The collaboration has resulted in many international publications and also the start of the Center for Immunopharmacology in Transplantation (IMUP).
Psychopharmacology department, Diakonhjemmet Hospital
The metabolism of psychotropic drugs is mainly mediated via different CYP enzymes of which different genotypes have been described. The use of patient genotyping to better understand the efficacy/adverse event of these drugs has been a main focus of our cooperation.
Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg
In order to limit the nutritional uptake in morbidly obese patients they may be subjected to bariatric surgery. The stomach size is reduced and the length of the intestine is shortened in this type of surgery. The bioavailability of drugs will also be affected by this type of surgery and this is a unique human model for investigation of the mechanisms that determine drug bioavailability. The PK-group has in collaboration with the Morbid Obesity Centre performed clinical trials where the effect of different types of bariatric surgery on atorvastatin bioavailability has been investigated.
The Lipid Clinic, OUS-Rikshospitalet
Statins (HMG-CoA reductase inhibitors) are cholesterol lowering drugs used by many patients. Statins are generally well tolerated but a relevant part of the population receiving these drugs develop myopatic side-effects. The PK-group has together with the Lipid Clinic investigated statin pharmacokinetic patterns in patients with myopathy and found that they show a distinct metabolite pattern.
Our main international collaborating partners:
- University of Rhode Island, USA
- University of Sheffield, UK
- Roche Molecular Systems, Pleasanton, CA, USA
- AstraZeneca AB, Mölndal, Sweden
- Cellartis AB, Gothenburg, Sweden